Tests bee venom injections for bone and mineral problems in kidney dialysis patients
Tests bee venom injections against standard care in adults on hemodialysis.
Plain-language title generated from the registry record
Registry title: Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have been on hemodialysis three times a week for at least six months. It tests bee venom injections against standard care for mineral and bone problems linked to kidney disease.
- Age
- 18 years and older
- Sex
- Women and men can join.
- Disease stage
- Chronic kidney disease treated with maintenance hemodialysis, three times a week for at least six months.
- Earlier treatment
- Must have been on hemodialysis for at least six months. Must not have used medicines that affect bone metabolism (for example calcitonin, denosumab, estrogen) in the last six months.
Main reasons for not taking part
- Pregnant or breastfeeding
- History of liver disease, cancer, or autoimmune disease
- Active long-term infection, including HIV, HCV, HBV, or tuberculosis
- Failure of a transplanted kidney within the past year
- Kidney transplant planned within the next year
This trial only enrols participants on dialysis. The registry sentence this rests on: Patients undergoing maintenance hemodialysis three times weekly for at least six months.
Read by machine on 12 November 2026.
Where in Egypt
- Urology and Nephrology Center, Mansoura UniversityAl Mansurah, EgyptContact: Muhammed A Elhadedy, MD NephrologyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Mansoura University
- Trial code
- NCT06901102
- Record updated
- 28 March 2025
- Original description
This study aims to evaluate the effectiveness of bee venom injections as a treatment for chronic kidney disease (CKD)-mineral bone disorder (MBD) in patients undergoing hemodialysis. MBD is a common complication in CKD patients, leading to abnormal mineral metabolism, bone disease, and increased cardiovascular risks. Current treatments are often inadequate and can have significant side effects.Read full original descriptionShow less
Bee Venom As Immunomodulator and Its Effect on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Prospective Randomized Controlled Trial
This study aims to evaluate the effectiveness of bee venom injections as a treatment for chronic kidney disease (CKD)-mineral bone disorder (MBD) in patients undergoing hemodialysis. MBD is a common complication in CKD patients, leading to abnormal mineral metabolism, bone disease, and increased cardiovascular risks. Current treatments are often inadequate and can have significant side effects.
In this study, we will compare the effects of bee venom injections with standard care treatments in hemodialysis patients. Bee venom is known for its potential anti-inflammatory and immunomodulatory properties, which may help improve mineral metabolism and bone health regulation in these patients. By stimulating regulatory T cells (Tregs) through bee venom, we aim to reduce inflammation and restore bone health.
We hope to answer whether bee venom can effectively reduce mineral bone disorder markers (such as calcium, phosphorus, and parathyroid hormone levels) and improve bone density in hemodialysis patients. The results could lead to a new treatment option for CKD-MBD, improving patient outcomes and quality of life.
Inclusion: Patients of both sexes aged 18 years and older; Patients undergoing maintenance hemodialysis three times weekly for at least six months; Patients who are not scheduled for kidney transplantation within the next year.
Exclusion: Current use of medications affecting bone metabolism (e.g., calcitonin, denosumab, estrogen) within the last six months; Medical history of chronic conditions such as liver disease, cancer, or autoimmune diseases; Active chronic infections, including HIV, HCV, HBV, and tuberculosis; History of renal allograft failure within the past year; Current pregnancy or lactation; Refusal to participate in the study.